5 most widely read First Opinions of 2019 – STAT
In 2019, 600-plus First Opinion authors addressed everthing from the opioid crisis to getting bad news from 23andMe. Here are the most widely read ones.
Related Articles
ScienceAdviser: Even cats think they’re liquids
Today in Science and science: Claims of ‘dark oxygen’ invite skepticism, an unexpected model for transmissible cancer, and more
In race to make gene therapy for age-related blindness, 4D Molecular announces positive results
While most gene therapy research has focused on rare disease, new results are out for a possible treatment for wet-AMD, the leading cause of age-related…
Social media diss highlights high-stakes rivalry over colon cancer blood tests
A rival CEO’s confrontational social media post underscored the high stakes in the race to develop and deploy cancer screening tests.
Social media diss highlights high-stakes rivalry over colon cancer blood tests
A rival CEO’s confrontational social media post underscored the high stakes in the race to develop and deploy cancer screening tests.
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% | Roivant Sciences Ltd.
VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication…
Independent Directors of 23andMe Resign from Board
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) — The independent directors of the Board of 23andMe Holding Co. (Nasdaq: ME), today sent the…
U.S. agency threatens J&J with sanctions if it switches payments to 340B hospitals
A U.S. government agency has threatened Johnson & Johnson with sanctions if the company proceeds with plans to alter payment methods for some hospitals.
Express Scripts sues FTC over a ‘biased’ report about pharmacy benefit managers
Express Scripts, one of the largest pharmacy benefit managers in the U.S., filed a lawsuit demanding that a recent FTC report on industry middlemen be…
Genentech, a biotech with a storied past, confronts new turbulence in the present
Genentech is a biotech company with a storied past. But what will happen in its future?
Most cardiovascular devices with serious safety recalls aren’t tested in patients
The analysis comes as regulators investigate how the FDA authorizes medical devices and handles safety recalls.